13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • FIG

    Acronym: 

    FIG

    ACTRN/NCT /ethics: 

    ACTRN12619001735145

    Scientific title: 

    Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)

    Summary of trial and patient characteristics

    Cancer Type Brain & central nervous system
    Trial Type Early detection, diagnosis, prognosis
    Phase All phases Tumour Stream Glioma
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date 2020-02-03
    Molecular Target Anticipated End Date 2022-02-01
    Cancer Type Brain & central nervous system
    Trial Type Early detection, diagnosis, prognosis
    Phase All phases
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Glioma
    Cancer Stage
    Anticipated Start Date 2020-02-03
    Anticipated End Date 2022-02-01

    Trial Summary

    The aim of this study is to evaluate the the PET imaging agent, O-(2-[18F]-fluoroethyl)L-tyrosine (FET) to definitively establish the role of FET-PET in the management of brain cancer (Glioblastoma).

    Lay Summary

    Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Peter Gorayski Not Yet Recruiting